Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Lung Cancer | Research

Targeting multiple genes containing long mononucleotide A-T repeats in lung cancer stem cells

Authors: Narumol Bhummaphan, Piyapat Pin-on, Preeyaporn Plaimee Phiboonchaiyanan, Jirattha Siriluksana, Chatchawit Aporntewan, Pithi Chanvorachote, Apiwat Mutirangura

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Intratumour heterogeneous gene expression among cancer and cancer stem cells (CSCs) can cause failure of current targeted therapies because each drug aims to target the function of a single gene. Long mononucleotide A-T repeats are cis-regulatory transcriptional elements that control many genes, increasing the expression of numerous genes in various cancers, including lung cancer. Therefore, targeting A-T repeats may dysregulate many genes driving cancer development. Here, we tested a peptide nucleic acid (PNA) oligo containing a long A-repeat sequence [A(15)] to disrupt the transcriptional control of the A-T repeat in lung cancer and CSCs.

Methods

First, we separated CSCs from parental lung cancer cell lines. Then, we evaluated the role of A-T repeat gene regulation by counting the number of repeats in differentially regulated genes between CSCs and the parental cells of the CSCs. After testing the dosage and effect of PNA-A15 on normal and cancer cell toxicity and CSC phenotypes, we analysed genome-wide expression to identify dysregulated genes in CSCs.

Results

The number of A-T repeats in genes differentially regulated between CSCs and parental cells differed. PNA-A15 was toxic to lung cancer cells and CSCs but not to noncancer cells. Finally, PNA-A15 dysregulated a number of genes in lung CSCs.

Conclusion

PNA-A15 is a promising novel targeted therapy agent that targets the transcriptional control activity of multiple genes in lung CSCs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.CrossRef Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.CrossRef
2.
go back to reference Cao L, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71.CrossRef Cao L, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71.CrossRef
3.
go back to reference Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine. 2012;7(4):597–615.CrossRef Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine. 2012;7(4):597–615.CrossRef
4.
go back to reference Nan X, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):75712–26.CrossRef Nan X, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):75712–26.CrossRef
5.
go back to reference Aporntewan C, et al. Upstream mononucleotide A-repeats play a cis-regulatory role in mammals through the DICER1 and Ago proteins. Nucleic Acids Res. 2013;41(19):8872–85.CrossRef Aporntewan C, et al. Upstream mononucleotide A-repeats play a cis-regulatory role in mammals through the DICER1 and Ago proteins. Nucleic Acids Res. 2013;41(19):8872–85.CrossRef
6.
go back to reference Pin-On P, et al. Targeting high transcriptional control activity of long mononucleotide A-T repeats in cancer by Argonaute 1. Gene. 2019;699:54–61.CrossRef Pin-On P, et al. Targeting high transcriptional control activity of long mononucleotide A-T repeats in cancer by Argonaute 1. Gene. 2019;699:54–61.CrossRef
7.
go back to reference Bhummaphan N, Chanvorachote P. Gigantol suppresses cancer stem cell-like phenotypes in lung cancer cells. Evid Based Compl Alt Med. 2015;2015:836564. Bhummaphan N, Chanvorachote P. Gigantol suppresses cancer stem cell-like phenotypes in lung cancer cells. Evid Based Compl Alt Med. 2015;2015:836564.
9.
go back to reference Bhummaphan N, et al. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression. Phytomedicine. 2019;62:152932.CrossRef Bhummaphan N, et al. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression. Phytomedicine. 2019;62:152932.CrossRef
10.
go back to reference Bhummaphan N, et al. cancer stem cell-suppressing activity of chrysotoxine, a Bibenzyl from Dendrobium pulchellum. J Pharmacol Exp Ther. 2018;364(2):332–46.CrossRef Bhummaphan N, et al. cancer stem cell-suppressing activity of chrysotoxine, a Bibenzyl from Dendrobium pulchellum. J Pharmacol Exp Ther. 2018;364(2):332–46.CrossRef
11.
go back to reference Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. Am J Physiol Cell Physiol. 2016;310(9):C728-39.CrossRef Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. Am J Physiol Cell Physiol. 2016;310(9):C728-39.CrossRef
12.
go back to reference Mandal M, et al. BRWD1 orchestrates epigenetic landscape of late B lymphopoiesis. Nat Commun. 2018;9(1):3888.CrossRef Mandal M, et al. BRWD1 orchestrates epigenetic landscape of late B lymphopoiesis. Nat Commun. 2018;9(1):3888.CrossRef
13.
go back to reference You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology. 2010;51(5):1635–44.CrossRef You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology. 2010;51(5):1635–44.CrossRef
14.
go back to reference Li Q, et al. miR-449a targets Flot2 and inhibits gastric cancer invasion by inhibiting TGF-β-mediated EMT. Diagn Pathol. 2015;10:202.CrossRef Li Q, et al. miR-449a targets Flot2 and inhibits gastric cancer invasion by inhibiting TGF-β-mediated EMT. Diagn Pathol. 2015;10:202.CrossRef
15.
go back to reference Papageorgis P. TGF β signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J Oncol. 2015;2015:587193.CrossRef Papageorgis P. TGF β signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J Oncol. 2015;2015:587193.CrossRef
17.
go back to reference Hu R, et al. SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway. Cancer Cell Int. 2018;18(1):183.CrossRef Hu R, et al. SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway. Cancer Cell Int. 2018;18(1):183.CrossRef
18.
go back to reference Boesch M, et al. Heterogeneity of cancer stem cells: rationale for targeting the stem cell niche. Biochem Biophys Acta. 2016;1866(2):276–89.PubMed Boesch M, et al. Heterogeneity of cancer stem cells: rationale for targeting the stem cell niche. Biochem Biophys Acta. 2016;1866(2):276–89.PubMed
19.
go back to reference Hiramatsu Y, et al. Arid1a is essential for intestinal stem cells through Sox9 regulation. Proc Natl Acad Sci USA. 2019;116(5):1704–13.CrossRef Hiramatsu Y, et al. Arid1a is essential for intestinal stem cells through Sox9 regulation. Proc Natl Acad Sci USA. 2019;116(5):1704–13.CrossRef
20.
go back to reference Myant KB, et al. Rac1 drives intestinal stem cell proliferation and regeneration. Cell Cycle. 2013;12(18):2973–7.CrossRef Myant KB, et al. Rac1 drives intestinal stem cell proliferation and regeneration. Cell Cycle. 2013;12(18):2973–7.CrossRef
21.
go back to reference Xu M, et al. (2018) Role of p38γ MAPK in regulation of EMT and cancer stem cells. Biochimica et Biophysica Acta BBA Mol Basis Dis. 1864;11:3605–17. Xu M, et al. (2018) Role of p38γ MAPK in regulation of EMT and cancer stem cells. Biochimica et Biophysica Acta BBA Mol Basis Dis. 1864;11:3605–17.
22.
go back to reference Baek J-H, et al. PLOD3 promotes lung metastasis via regulation of STAT3. Cell Death Dis. 2018;9(12):1138.CrossRef Baek J-H, et al. PLOD3 promotes lung metastasis via regulation of STAT3. Cell Death Dis. 2018;9(12):1138.CrossRef
23.
go back to reference Cui N, et al. Epigenetic regulator ARID1A and stem cell transcription factor SOX9 in the maintenance of pancreatic ductal cell differentiation state and development of intraductal papillary mucinous neoplasia (IPMN) and pancreatic ductal adenocarcinoma (PDAC). Transl Cancer Res. 2018. https://doi.org/10.21037/tcr.2018.07.25.CrossRef Cui N, et al. Epigenetic regulator ARID1A and stem cell transcription factor SOX9 in the maintenance of pancreatic ductal cell differentiation state and development of intraductal papillary mucinous neoplasia (IPMN) and pancreatic ductal adenocarcinoma (PDAC). Transl Cancer Res. 2018. https://​doi.​org/​10.​21037/​tcr.​2018.​07.​25.CrossRef
24.
go back to reference Lu P, et al. p53-Bad: a novel tumor suppressor/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy. Mol Pharm. 2019;16(8):3386–98.CrossRef Lu P, et al. p53-Bad: a novel tumor suppressor/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy. Mol Pharm. 2019;16(8):3386–98.CrossRef
26.
go back to reference Inoue K, Fry EA. Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN network. Cancer Invest. 2018;36(9–10):520–36.CrossRef Inoue K, Fry EA. Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN network. Cancer Invest. 2018;36(9–10):520–36.CrossRef
27.
go back to reference Muthu M, Cheriyan VT, Rishi AK. CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis. Oncotarget. 2015;6(9):6499–510.CrossRef Muthu M, Cheriyan VT, Rishi AK. CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis. Oncotarget. 2015;6(9):6499–510.CrossRef
28.
go back to reference Pelullo M, et al. Wnt, Notch, and TGF-β pathways impinge on hedgehog signaling complexity: an open window on cancer. Front Genet. 2019;10:711.CrossRef Pelullo M, et al. Wnt, Notch, and TGF-β pathways impinge on hedgehog signaling complexity: an open window on cancer. Front Genet. 2019;10:711.CrossRef
29.
go back to reference Yang L, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.CrossRef Yang L, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.CrossRef
30.
go back to reference Abel EV, et al. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS ONE. 2014;9(3):e91983–e91983.CrossRef Abel EV, et al. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS ONE. 2014;9(3):e91983–e91983.CrossRef
31.
go back to reference Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141–60. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141–60.
32.
go back to reference Tang Y, et al. ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines. Oncol Rep. 2014;32(5):2168–74.CrossRef Tang Y, et al. ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines. Oncol Rep. 2014;32(5):2168–74.CrossRef
Metadata
Title
Targeting multiple genes containing long mononucleotide A-T repeats in lung cancer stem cells
Authors
Narumol Bhummaphan
Piyapat Pin-on
Preeyaporn Plaimee Phiboonchaiyanan
Jirattha Siriluksana
Chatchawit Aporntewan
Pithi Chanvorachote
Apiwat Mutirangura
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02902-6

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.